Product Description
For Dry Eye Syndrome
Mechanisms of Action: Type 2 Collagen Stimulant
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Laboratorios Sophia S.A de C.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Dry Eye Syndromes|Keratoconjunctivitis Sicca
Phase 1: Environmental Hypersensitivity|Keratoconjunctivitis Sicca|Dry Eye Syndromes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PRO-087 | P4 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2023-05-15 |
|
| 087LATAMFIV | P4 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2018-10-16 |
|
| PRO-087/I | P1 |
Completed |
Keratoconjunctivitis Sicca|Environmental Hypersensitivity|Dry Eye Syndromes |
2018-02-12 |
22% |